RxDoctor Payments DataLook up a doctor →

James Norris

Medical · Morehead City, NCNPI 1639615065

Payments from drug & device makers

$10,372in general payments, 2019–2025

Across 476 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intra-sana Laboratories$3K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Amgen$813
  • Lilly USA, LLC$642
  • GSK$379
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$3,00029%
  • Food & beverage$7,36071%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,372 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$82,241
Medicare patients
206
Services billed
1,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$84,475
OzempicSemaglutide52$82,852
JardianceEmpagliflozin43$55,915
FarxigaDapagliflozin Propanediol34$46,273
EliquisApixaban55$35,586
RybelsusSemaglutide15$35,391
VraylarCariprazine Hcl17$30,090
Soliqua 100-33Insulin Glargine/Lixisenatide15$23,698
TrulicityDulaglutide12$17,528
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$15,318
Repatha SureclickEvolocumab17$13,336
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$12,860
EntrestoSacubitril/Valsartan17$10,723
Synjardy XrEmpagliflozin/Metformin Hcl11$6,476
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,122$118,24367 claims
Lilly USA, LLCMounjaro, Trulicity$642$102,00377 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr$214$75,25167 claims
AstraZenecaFarxiga, Breztri Aerosphere$284$61,59045 claims
PfizerEliquis$262$35,58655 claims
AbbVieVraylar, Synthroid$1,085$31,49135 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$213$23,69815 claims
NovartisEntresto$52$10,72317 claims
GSKAnoro Ellipta, Shingrix$379$8,55826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.

Other medical in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →